infliximab
janssen
['#1112', 'danbio']
nabi. biosimilar to biosimilar ifx switch in danbio. high retention rate - 92% in originator-experienced equiv to normal drop off at 1 year on a biologic. lower retention 83% in originator-naive switchers = likely nocebo effect #acr22 abstr#1112 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC